Feb 23, 2017 12:01 pm UTC| Business
Design targets FCC plans for licensing 28GHz communications band Phased array technology available now to meet emerging billion dollar 5G markets TowerJazz, the global specialty foundry leader, and The University of...
Feb 23, 2017 12:01 pm UTC| Business
Design targets FCC plans for licensing 28GHz communications band Phased array technology available now to meet emerging billion dollar 5G markets TowerJazz, the global specialty foundry leader, and The University of...
RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results
Feb 23, 2017 12:01 pm UTC| Business
RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and U.S. commercialization...
RedHill Biopharma Reports 2016 Fourth Quarter and Full-Year Financial Results
Feb 23, 2017 12:01 pm UTC| Business
RedHill maintains a strong and debt-free balance sheet with approximately $66 million in cash and cash equivalents at the end of 2016, allowing the Company to continue to execute its development and U.S. commercialization...
KEMET Announces Agreement to Acquire NEC TOKIN
Feb 23, 2017 12:01 pm UTC| Business
GREENVILLE, S.C., Feb. 23, 2017 -- KEMET Corporation (the “Company” or “KEMET”) (NYSE:KEM), a leading global supplier of passive electronic components, announced today that, through its wholly owned subsidiary, KEMET...
KEMET Announces Agreement to Acquire NEC TOKIN
Feb 23, 2017 12:01 pm UTC| Business
GREENVILLE, S.C., Feb. 23, 2017 -- KEMET Corporation (the “Company” or “KEMET”) (NYSE:KEM), a leading global supplier of passive electronic components, announced today that, through its wholly owned subsidiary, KEMET...
Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
Feb 23, 2017 12:01 pm UTC| Business
ORLANDO, Fla., Feb. 23, 2017 -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment...